News

Pharmaceutical Technology on MSN20h
Sanofi and Regeneron report results from two Phase III trials of COPD treatment
Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.
REGN Stock Undervalued At $500?
In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Regeneron (REGN) Downgraded at RBC Capital, Price Target Cut Sharply
RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...